Introduction
Members of the transforming growth factor-b (TGF-b) family have been implicated in the regulation of cell growth, differentiation, apoptosis, adhesion, and motility (Roberts and Sporn, 1990; Wall and Hogan, 1994; Moses and Serra, 1996) . Abnormal activation or inhibition of these TGF-b regulated processes is implicated in many diseases including cancer. Ligands in this family include three mammalian TGF-bs, activins, and bone morphogenetic proteins (BMPs). TGF-b superfamily members signal through a family of transmembrane receptors with intrinsic cytoplasmic serine/threonine kinase activity (Massague´, 1998) . Ligand binding to heteromeric receptor complex consisting of both type I (TbRI) and type II (TbRII) induces carboxy-terminal serine phosphorylation of a set of cytoplasmic signal-transducing proteins collectively referred to as 'Smad' proteins (Heldin et al., 1997; Derynck et al., 1998) . Pathway-specific Smads consist of Smads 1, 5, and 8 that mediate BMP signaling and Smads 2 and 3 that mediate TGF-b and activin signaling (Derynck et al., 1998) . Phosphorylated pathway-specific Smads heterodimerizes with Smad4 (a common mediator of all of the pathway-specific Smads) and this complex translocates into the nucleus to activate transcription of various target genes (Massague´and Wotton, 2000) .
TGF-b plays a complicated, biphasic role in cancer. Early in the course of cancer development, TGF-b acts as a tumor suppressor through its ability to suppress proliferation (Wakefield and Roberts, 2002) . However, TGF-b appears to act as a tumor enhancer in later stages of carcinogenesis. For example, many tumors have increased production of TGF-b, which could benefit the cancer cells indirectly through production of extracellular matrix, suppression of immune system function, or promotion of angiogenesis. Nearly every component of the TGF-b pathway can be altered in cancer, with the three main targets appearing to be TGF-b receptors, Smads, and target genes. The loss of expression of TbRII in association with resistance to the growth inhibitory effect of TGF-b has been reported in various types of cancers, including gastric, colon, breast, and prostate (Park et al., 1994; Markowitz et al., 1995; Hahm et al., 1999; Kim et al., 2000) . TGF-b signaling is also impaired by deletions or mutations in the Smads which normally act downstream of the receptor. Smad4 was originally identified as a tumor suppressor gene lost in pancreatic cancers, deleted in pancreatic cancer locus 4 (DPC4) (Hahn et al., 1996) . Smad4, located in 18q21, is also altered in colorectal cancers (Calonge and Massague´, 1999 ) with a higher incidence of mutation in metastatic colon carcinomas (Schutte, 1999; Fink et al., 2001) . Studies have shown a mutated Smad2 gene in colorectal and lung cancers although this gene is a less frequent target than Smad4 gene (Riggins et al., 1997; Takagi et al., 1998; Takenoshita et al., 1998; Yanagisawa et al., 2000) . However, to date, there is no evidence that Smad3 is the locus of homozygous deletions, functionally inactivating mutations, or amplifications in human malignancy. A recent study also showed that no acquired clonal mutations, insertions, or microdeletions in Smad3 were detected in parathyroid adenomas and enteropancreatic tumors that were highly linked to multiple endocrine neoplasia type 1 (Shattuck et al., 2002) . Smad3 null mice are viable and have a variable phenotype depending on the genetic background. One group has shown 100% penetrance of metastatic colon carcinoma (Zhu et al., 1998) , while other groups have shown no malignancies (Datto et al., 1999; Yang X et al., 1999) . There was the suggestion that although Smads 4 and 2 have tumor suppressor activities, Smad3 may contribute to the oncogenic activities of TGF-b (de Caestecker et al., 2000) . Therefore, the controversy remains as to whether Smad3 functions as a tumor suppressor or not.
In gastric cancer, no mutations in the Smad2 gene have been reported (Shitara et al., 1999) . Loss of Smad4 was frequently found in gastric cancer (Powell et al., 1997) and tumors with reduced Smad4 expression showed poorer clinical outcome than those with preserved expression (Xiangming et al., 2001) . However, until now, no study has been specifically addressed to ascertain the precise role of Smad3 in the progression of gastric carcinoma. In this study, we found that 37.5% of human gastric tumors showed low to undetectable levels of Smad3 expression while all neighboring normal tissue showed Smad3 expression. These data support the notion that deficient expression of Smad3 might play a role in carcinogenesis. We showed that introduction of Smad3 into SNU-484 human gastric cancer cells, which express a normal component of TGF-b receptor but are deficient in Smad3 restored TGF-b sensitivity as well as reduced tumorigenicity. Smad3-expressing SNU-484 cells also showed reduced expression of the angiogenic mediator, vascular epithelial growth factor (VEGF), and enhanced expression of the tumor suppressor E-cadherin. These results strongly indicate that the degree of malignancy of a subset of human gastric cancers is directly associated with loss of Smad3 expression, suggesting that Smad3 functions as a tumor suppressor.
Results

Smad3 protein expression in primary human gastric cancer tissues and human gastric cancer cell lines
To investigate the role of Smad3 in carcinogenesis, we examined expression of Smad3 in human gastric cancer tissues. Eight pairs of human gastric tissues and surrounding normal mucosa were used in this study.
Western blot analysis showed that all normal mucosa expressed Smad3 protein, but three of eight (37.5%) gastric cancer tissues showed undetectable level of Smad3 (Figure 1a ). This suggests that suppression of Smad3 may play a role in gastric carcinogenesis.
We also examined expression of Smad2, Smad3, and Smad4 proteins in nine human gastric cancer cell lines and compared them with the TGF-b1 responsiveness that was previously reported from our laboratory (Park et al., 1994; Chang et al., 1997; Kang et al., 1999) . Among nine gastric cancer cell lines, SNU-16, SNU-620 and SNU-719 retained TGF-b sensitivity. SNU-5 and SNU-668 cell lines demonstrated deletion of the TbRII gene (Yang H-K et al., 1999) . A frameshift mutation affecting a 10-base pair (bp) polyadenine repeat that is Step RT-PCR was performed using 100 ng of total RNA isolated from SNU-1, SNU-5, SNU-484, and SNU-638 cells. The target transcript was reverse transcribed at 501C for 1 h and amplified using 24 PCR cycles; RT-PCR products were analysed via agarose/ EtBr gel electrophoresis present in the TbRII coding region was previously described in SNU-1 and SNU-638 cell lines (Myeroff et al., 1995) . In the nine human gastric cancer cells examined, all cell lines expressed Smad2. Smad3 protein was detected in , and -719 cell lines (Figure 1b) . However, SNU-1 and SNU-484 cells expressed low to undetectable levels of Smad3. Smad4 was expressed in most of the gastric cancer cell lines except SNU-601 cells, which expressed low to undetectable levels. All TGF-b-responsive cells expressed Smads 2, 3, and 4, and had a wild-type TbRII gene. This finding suggests that intact TGF-b signaling requires TbRII, Smads 2, 3, and 4. Interestingly, expression of E-cadherin, which is an important adhesion molecule and known tumor suppressor, correlated perfectly with intact TGF-b signaling. To see whether gross structural defects of the Smad3 gene were present in SNU-484 cells, we examined the genomic structure of the Smad3 gene in SNU-484 cell and SNU-620 cell lines utilizing PCR-based methods using specific primers for each exon. Gross structural genomic alteration of the Smad3 gene was not observed in these cell lines (data not shown), suggesting that the absence of Smad3 protein expression in SNU-484 cells may be caused by transcriptional repression. Next, we checked the mRNA level of Smad3 using reverse transcription PCR (RT-PCR). The expression level of Smad3 mRNA in SNU-1 and SNU-484 was significantly reduced compared to that of SNU-5 and SNU-638 ( Figure 1c ). RT-PCR results were correlated well with Smad3 protein levels examined by Western blot analysis (Figure 1b and c).
Introduction of Smad3 restored TGF-b signaling in SNU-484 cells
Restoration of TGF-b signaling by the introduction of Smad3 has been reported in fibroblasts derived from mouse embryos deficient in Smad3. Induction of expression of Smad7, TGF-b1, and PAI-1 genes by TGF-b1 was restored after stable reintroduction of Smad3 in these primary Smad3-deficient fibroblasts (Piek et al., 2001) . However, the restoration of TGF-b signaling and suppression of tumorigenicity by the introduction of Smad3 in tumor cells, which have lost the Smad3 expression has not been reported. Among SNU-1 and SNU-484 cell lines that express low to undetectable levels of Smad3, only SNU-484 cells have an intact TbRII gene. To confirm that TGF-b insensitivity in SNU-484 cells is due to the low level of Smad3, we tested the ability of TGF-b to activate p3TP-Lux or the SBE-Luc reporter which contains four repeats of Smad-binding element (SBE) driving a luciferase reporter (Zawel et al., 1998) . As shown in Figure To investigate whether stable overexpression of Smad3 could restore TGF-b sensitivity in cells with low to undetectable levels of Smad3, SNU-484 cells were infected with either LPCX-Smad3 or LPCX virus. LPCX-Smad3 and LPCX SNU-484 clones were selected after retroviral delivery of expression constructs. Western blot analysis revealed that SNU-484 cells infected with a construct encoding wild-type Smad3 (SNU-484-S3-1, SNU-484-S3-2) expressed high levels of Smad3 protein compared with both parental SNU-484 and control LPCX-transfected cells (SNU-484-LPCX) ( Figure 3a ). To assess restoration of TGF-b signaling, we transfected the SBE-luc reporter construct into SNU-484-S3-1 cells or control cells (SNU-484-LPCX). Exogenous TGF-b1 induced luciferase activity more than twofold in SNU-484-S3-1 cells and produced no observable induction in control cells (Figure 3b ). Similar results were also obtained with SNU-484-S3-2 cells (data not shown). Therefore, we have used SNU-484-S3-1 cells for the following experiments.
To investigate whether expression of Smad3 could also restore TGF-b-dependent inhibition of cell growth Role of Smad3 expression in gastric tumor suppression S-U Han et al in SNU-484 cells, we compared cell proliferation for both Smad3 transfected and control LPCX transfected clones. The growth rate of SNU-484-S3-1 was very similar to SNU-484-LPCX. However, the addition of TGF-b1 significantly inhibited the proliferation of Smad3-expressing cells compared to control cells (Figure 3c ). This finding confirms the restoration of TGF-b signaling in Smad3-expressing SNU-484 cells. TGF-b-induced cell cycle arrest activates cyclin-dependent kinase inhibitors such as p15 or p21 in TGF-bresponsive human gastric cancer cells . Protein expression of p15 and p21 was examined by Western blot analysis 24 h after TGF-b1 treatment in Smad3-expressing SNU-484 cells. There was a slight increase in the basal expression of both p15 and p21 proteins in Smad3-expressing SNU-484 cells and the expression level was markedly increased after TGF-b1 treatment (Figure 3d ). We next checked the level of VEGF, known to be a key angiogenic mediator. VEGF protein levels in Smad3-expressing SNU-484 cell lysates were significantly decreased (Figure 3d ). Cyclin D1 was previously shown to be a target of TGF-b (Jong et al., 2002) , and has been implicated in TGF-b-induced growth arrest. Cyclin D1 protein level was also decreased in Smad3-expressing SNU-484 cells. Since E-cadherin is an important adhesion molecule and wellknown tumor suppressor in human gastric cancer (Keller, 2002) , we examined expression of E-cadherin by Western blot analysis. Basal expression of E-cadherin was markedly increased in Smad3-expressing SNU-484 cells (Figure 3d ). However, TGF-b treatment did not enhance level of E-cadherin expression. These findings suggest that Smad3 has a tumor suppressive role.
Smad3 showed tumor suppression activity in tumorigenicity study
To test whether resoration of TGF-b signaling by the introduction of Smad3 into SNU-484 cells might render these cells less tumorigenic, exponentially growing Smad3-expressing SNU-484 cells (SNU-484-S3-1) and control cells (SNU-484-LPCX) were inoculated into athymic nude mice at a dose of 5 Â 10 6 cells per site, and the mice were monitored for progression of xenograft formation. At 4 weeks after inoculation, palpable tumors were detected. The growth of xenografts was significantly delayed in all mice injected with SNU-484-S3-1 cells compared to that of control cells (Figure 4) . Moreover, when tumor burden was measured at 10 weeks after inoculation, the xenograft size of SNU-484-S3-1 cells was less than 15% of that of control tumors. Upon resection, tumors from SNU-484-LPCX cells showed severe hypervascularity ( Figure 5 ). Almost (Figure 6a ) that was compatible with the in vitro study. Immunohistochemical staining showed intercellular localization of E-cadherin in tumors from SNU-484-S3-1 cells (Figure 6b ). CD31 was used for microvessel staining. Tumors from SNU484-LPCX cells showed massive infiltration of microvessels, but those of SNU484-S3-1 showed little infiltration (Figures 5c and 6c) . These results suggest that expression of Smad3 most significantly inhibits in vivo growth of SNU-484 cells through restoration of TGF-b signaling and tumor-suppressor activity.
Discussion
In this study, we have shown that Smad3 expression is suppressed in a subset of human gastric cancers and human gastric cancer cell lines and that restoration of TGF-b signaling by transfecting Smad3 in Smad3-deficient gastric cancer cells induced tumor suppressive activity. Importantly, we have shown that recovery of TGF-b signaling induced the tumor suppressor, Ecadherin. E-cadherin expression was perfectly correlated with the TGF-b responsiveness of the nine gastric cancer cell lines examined in this study, suggesting that intact TGF-b signaling is important for the expression of Ecadherin.
Mutation in genes that inhibit the formation of tumors has long been known to be one of the main driving forces in the development of cancer. Point mutations, deletions, insertions, amplifications and translocations have all been shown to be responsible for activation of oncogenes or inactivation of tumor suppressors, leading to the development of tumors (Fearon and Vogelstein, 1990) . However, in recent years it has become increasingly obvious that genetic abnormalities are by no means the only mechanism by which gene expression becomes altered during tumorigenesis. Growing evidence now indicates that epigenetic factors play a major role in carcinogenesis and indeed may be as significant as the more widely studied genetic abnormalities. Tumor cells often become resistant to TGF-b-induced growth inhibition and apoptosis due to functional inactivation of TGF-b receptors and Smads. Inactivated Smads 2 and 4 have been found due to deletion or mutation in their genes (Hahn et al., 1996; Riggins et al., 1997; Takagi et al., 1998; Schutte, 1999; Blobe et al., 2000; de Caestecker et al., 2000; Massague´and Chen, 2000; Yanagisawa et al., 2000; Derynck et al., 2001; Fink et al., 2001) . In contrast to known tumor suppressors Smads 2 and 4, the tumor suppressive role of Smad3 has not been clarified because mutations in the Smad3 gene have thus far not been discovered in human tumors. Certain oncogene products have been shown to functionally inactivate Smad3. Chromosomal rearrangements resulting in the fusion products AML/Evi-1 (Kurokawa et al., 1998) or AML/MDS/Evi-1 (Sood et al., 1999) are frequent in myeloid leukemia and myelodysplasia. Both fusion proteins interact with and functionally inactivate Smad3, interfering with growth inhibition of myeloid cells by TGF-b, suggesting that Evi-1 may interfere with TGF-b signaling mediated by Smad3 in these tumors. The oncoprotein c-Ski is frequently involved in chromosomal translocations associated with non-Hodgkin's lymphoma and pre-B acute lymphoblastic leukemia, again potentially suppressing the activity of Smad3 (Akiyoshi et al., 1999; Luo et al., 1999) . Infection of cells with human T-cell lymphotropic virus-1 (HTLV-1) and human papillomavirus (HPV) also modulates TGF-b signaling. The HTLV-I oncoprotein Tax is implicated in the various clinical manifestations associated with infection by HTLV-1 including an aggressive and fatal T-cell malignancy. HTLV-1-infected T-cell lines became resistant to TGF-b growth inhibitory activity. Recently, we have shown that Tax suppresses TGF-b signaling through direct interaction with Smad proteins, indicating that the inhibition of TGF-b signaling by Tax may lead to the HTLV-1-associated leukemogenesis (Lee et al., 2002a) . The HPV oncoprotein E7 is implicated in the etiology of cervical cancer associated with infection by HPV. We have also demonstrated that E7 interacts constitutively with Smads 2, 3, and 4, and blocks Smad3 binding to its target sequence on DNA, suggesting that suppression of Smad-mediated signaling by E7 may contribute to HPV-associated carcinogenesis (Lee et al., 2002b) . These findings suggest that aberrant expression of Smad3 inhibitors may contribute to the functional inactivation of Smad3, providing promotion of tumor growth.
Recent studies have shown that the Runt domain transcription factors, RUNX1, RUNX2 and RUNX3, are integral components of signaling cascades mediated by both TGF-b and BMPs in several important biological systems (Ito and Miyazono, 2003 ). RUNX3 appears to be a tumor suppressor of gastric cancer and an important component of the TGF-b-induced tumor suppressor pathway. RUNX3 is expressed in glandular stomach epithelial cells, and the RUNX3 null gastric mucosa develops hyperplasias due to promotion of proliferation and suppression of apoptosis in epithelial cells (Li et al., 2002) . RUNX3 (PEBP2aC/CBFA3/ AML2) is known to form a complex with Smad3 and stimulates its transcriptional activity . Since gross structural genomic alteration of the Smad3 gene and mutation in exons of the Smad3 gene were not observed in SNU-484 cell line, which suggests that Smad3 gene is transcriptionally repressed in SNU-484 cells, it will be interesting to see whether RUNX3 regulates Smad3 expression and whether RUNX3 expression is lost in SNU-484 cells.
Neovascularization through the induction of angiogenesis is a prerequisite for the growth of solid tumors beyond a microscopic size (Bouck et al., 1996; Hanahan and Folkman, 1996) . For tumors to develop in size and metastatic potential they must make an 'angiogenic switch' through perturbing the local balance of proangiogenic and antiangiogenic factors. Frequently, tumors overexpress proangiogenic factors, such as VEGF, allowing them to make this angiogenic switch (Hanahan and Folkman, 1996) . There is accumulating evidence that tumor suppressors may act in part through suppression of angiogenesis. p53 (Dameron et al., 1994; Kieser et al., 1994; Mukhopadhyay et al., 1995) and p16 (Harada et al., 1999) has been implicated in downregulation of VEGF. Herein, we show that reexpression of Smad3 in gastric cancer cells decreased expression levels of VEGF and CD31. Both changes were sufficient to shift the angiogenic phenotype of SNU484 cells to antiangiogenic. The angiogenic switch seen in vitro was maintained in vivo, where Smad3-expressing cells formed small tumor nodules with reduced vascularization. Recent study has shown that the re-expression of Smad4 in pancreas carcinoma cells decreased expression levels of VEGF and increased the expression of TSP-1 and that Smad4-expressing cells induced small nonprogressive tumors with reduced vascular density (Schwarte-Waldhoff et al., 2000) . These results suggest that Smad-dependent TGF-b signaling may be involved in the control of an angiogenic switch.
E-cadherin is a cell adhesion molecule that is essential to maintaining the integrity of cell-cell contact in epithelial cell layers, and inactivation of E-cadherin is thought to be an important step in the development of most, if not all, epithelial-derived tumor types (Birchmeier and Behrens, 1994) . Mutations within the Ecadherin gene have been shown to be associated with familial gastric cancer (Guilford et al., 1998) and loss of expression of E-cadherin in sporadic gastric cancers is thought to be a key step in metastasis (Hirohashi, 1998) . Most of the studies on E-cadherin and cancer have focused on its role in suppression of metastasis (Christofori and Semb, 1999) . Loss of E-cadherin expression was demonstrated to be associated with increased invasiveness in many human tumor types (Birchmeier and Behrens, 1994) . Furthermore, reexpression of E-cadherin in cell culture results in reversion of the invasive phenotype (Frixen et al., 1991; Vleminckx et al., 1991) . In our study, reexpression of Smad3 in SNU-484 cells, which have deficient levels of Smad3 and E-cadherin, recovered the expression of E-cadherin. E-cadherin expression was observed in Smad3-expressing SNU-484 cells even in the absence of addition of exogenous TGF-b. It is possible that restoration of autocrine TGF-b signaling by introduction of Smad3 gene may trigger expression of Ecadherin. However, we cannot exclude the possibility that E-cadherin expression is dependent on Smad3 but independent of TGF-b. The liver of compound heterozygous Smad2 þ /À; Smad3 þ /À mice showed decreased expression of intercellular E-cadherin compared to that of wild type . In those mice, other extracellular matrix components such as collagen VI, connective tissue growth factor, fibronectin, vitronectin, and gelatinase B were expressed normally. These results suggest that the decreased expression of E-cadherin seen in the liver of Smad2 þ /À; Smad3 þ /À mice may be related to insufficient expression of Smads 2 and 3, and not secondary to other defects. Another study shows that re-expression of Smad4 in colon carcinoma cells induced tumor suppression combined with expression of E-cadherin (Mu¨ller et al., 2002) . Therefore, the expression of Smads might play a key role in the expression of E-cadherin.
In conclusion, our results demonstrate for the first time that Smad3 has a tumor suppressor function. We provide evidence that Smad3 may be involved in transcriptional regulation of the tumor suppressor Ecadherin. Importantly, Smad3-mediated induction of Ecadherin is retained in vivo in nude mouse tumors. We also found that recovery of Smad3 suppressed the expression of potent angiogenic mediator VEGF. Our findings suggest that pharmacological augmentation of Smad3 expression in human gastric cancer cells may be a useful therapeutic strategy in this disease.
Materials and methods
Patients
Tissue samples from eight patients with gastric adenocarcinomas were studied after surgical resection at Seoul National University Hospital in Korea. These tissues were frozen in liquid nitrogen immediately after resection in the operating room and stored at À701C until use, following the regulations of Seoul National University Hospital.
Cell lines and cell culture
Human gastric cancer cell lines, SNU-1, SNU-5, SNU-16, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668, and SNU-719, established from gastric carcinomas of individual patients were generously supplied by Dr Jae-Gahb Park (Seoul National University College of Medicine). Cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and maintained at 371C in an atmosphere of 5% CO 2 /95% air.
Western blot analysis
Exponentially growing cells in 10 cm 2 dishes were rinsed several times with phosphate-buffered saline and fed with RPMI 1640 supplemented with 10% fetal bovine serum containing 5 ng/ml TGF-b1. The cells were then cultured for 24 h in a humidified CO 2 incubator. Control cells were similarly washed and cultured in medium without TGF-b1. Protein extracts were heated at 951C for 5 min, separated by 4-20% SDS-PAGE, followed by Western blot analysis performed using anti-Smad2 (MHA2, Zymed, San Francisco, CA, USA), anti-Smad3 (LPC3, Zymed; TGB003, Boditech, Korea), anti-Smad4 (B-8, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-b-actin (A-5441, Sigma), anticyclin D1 (H-295, Santa Cruz Biotechnology, Inc.), anti-p15 (K-18, Santa Cruz Biotechnology, Inc.), anti-p21 (C-19, Santa Cruz Biotechnology, Inc.), anti-VEGF (sc-507, Santa Cruz Biotechnology, Inc.), and anti-E cadherin (13-1700, Zymed) antibodies.
Isolation of RNA and RT-PCR
Total RNA was isolated from human gastric cancer cells using Trizol (Gibco BRL, Gaithersburg, MD, USA). RT-PCR was performed according to the manufacturer's instruction using a TITANIUM TM One-Step RT-PCR kit (BD Biosciences Clontech, Palo Alto, CA, USA). The primers used were as follows: Smad3 (sense/antisense), 5 0 -AGAA GACGGGGCAGCTGGAC-3 0 /5 0 -GACATCGGATTCGGG GATAG-3 0 (product length: 511 bp) and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sense/ antisense), 5 0 -GCAGGGGGGAGCCAAAAGGG-3 0 /5 0 -TG-CCAGCCCCAGCGT CAAAG-3 0 (product length: 566 bp). RT-PCR was performed with a 50 ml volume. The amplification cycle (denaturation step at 941C for 30 s, and annealing step at 65.01C for 30 s, and an extension step at 681C for 1 min) was repeated 24 times and followed by a final extension for 2 min at 681C.
Transient transfection and luciferase assay
SNU-484 cells were seeded in six-well plates at 5 Â 10 5 cells/ wells as triplicates and transiently cotransfected with the 3TP-Lux reporter or SBE-Luc reporter and Smad3 DNA. A bgalactosidase reporter was also transfected as an internal control. We used Lipofectin (Life Technologies, Inc., Rockville, MD, USA) as a transfection agent according to the manufacturer's instructions. After transfection, cells were treated with 1, 3, and 5 ng of TGF-b1/ml for 24 h in media. All assays were performed in triplicate, and data shown represents the mean þ standard deviation (s.d.) of three independent transfections.
Retroviral infection and generation of stable cell lines
To generate Smad3-expressing retroviruses, Pheonix E packaging cells were plated at 10 6 cells/60-mm-diameter tissue culture dishes and transfected with the LPCX retroviral vector (empty or containing Flag-wild-type Smad3) by the calcium phosphate method. At 6 h post-transfection, the medium was replaced with fresh DMEM containing 10% FBS, and cells were grown for an additional 24 h. The conditioned medium containing recombinant retroviruses was collected and filtered through 0.45 mm-pore-size polysulfonic filters. Samples of these supernatants were applied immediately to SNU484 cells, which had been plated 18 h before infection at a density of 10 5 cells/60-mm-diameter tissue culture dishes. Polybrene (Sigma, St Louis, MO, USA) was added to a final concentration of 8 mg/ml and the supernatants were incubated with the cells for 12 h. After infection, the cells were placed in fresh growth medium and cultured as usual. Selections with 1 mg of puromycin/ml were initiated 24 h after infection. After 15 days, individual clones picked from plates of the recombinant retrovirus-infected cells were transferred to sixwell plates and expanded to generate cell clones stably expressing Smad3.
DNA synthesis study
To investigate whether expression of Smad3 could restore TGF-b sensitivity in SNU484 cells, we compared cell proliferation for both control SNU484 LPCX clones and SNU484 Smad3 clones. Cells were plated in 24-well dishes at a density of 5 Â 10 4 cells per well in 0.5 ml of assay medium (RPMI 1640 medium/10% fetal bovine serum). After incubating 24 h, both clones were treated with TGF-b1 (5 ng/ml). Cells growing in monolayers were pulse-labeled with 0.5 mCi of [
3 H]thymidine (1 Ci ¼ 37 GBq) for 2 h at 371C. Cells were then fixed with 1 ml of methanol/acetic acid, 3 : 1 (vol/vol) for an hour at room temperature, washed twice with 2 ml of 80% methanol, incubated at 371C with 500 ml of trypsin (0.2 mg/ml) for 30 min, fully solubilized with 500 ml of 1% SDS, and transferred to scintillation vials to measure radioactivity.
Tumorigenecity study
Cells (5 Â 10 6 in 200 ml PBS) from exponential cultures of SNU-484 cells expressing wild-type Smad3 and LPCX were inoculated into the subcutaneous tissues of 6-week-old male nude mice. A total of 10 mice were used respectively. Mice were maintained in a pathogen-free environment. Tumor growth rate was determined by measuring the xenografts in three dimensions. Volume (V) was determined using the equation V ¼ (L Â W 2 ) Â 0.5, in which V ¼ volume, L ¼ length, length, and W ¼ width.
Immunohistochemical staining
Tissues were fixed in 10% neutral buffered formalin, mounted in paraffin, and 5 mm sections were deparaffinized. Endogenous peroxidase was blocked with 3% H 2 O 2 in methanol for 30 min. Nonspecific protein binding was blocked with a solution containing 1% bovine serum albumin (BSA) and 5% goat serum for 30 min. Sections were incubated overnight with the primary antibodies (anti-E-cadherin (13-1700) 1 : 500, anti-CD31 (M57889, Pharmingen, San Diego, CA, USA) 1 : 500) in TBS/1% BSA in cold room. Antigen-antibody complexes were detected using the Vectastatin Elite avidinbiotin complex (ABC) peroxidase kit from Vector Laboratories (Burlingame, CA, USA) according to the manufacturer's instructions. After a 30-min incubation with ABC reagent, a 5-min reaction with 3,3 0 -diamino benzidine/H 2 O 2 (BioGenex) was used to detect the bound peroxidase. Slides were counterstained with Carazzi haematoxylin.
